MBTD1

Across TCGA pan-cancer cohorts, MBTD1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MBTD1 data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MBTD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MBTD1 expression acts as an unfavorable survival marker.

DLBC, COAD, and ESCA are the cancer types where MBTD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
COAD	OS	Median	IV	0.056	0.649	<.001	12	view →
ESCA	DFS	Median	III,IV	0.080	0.442	.007	6	view →
SKCM	OS	Median	III,IV	0.254	0.707	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MBTD1–DLBC (OS)

Open the DLBC breakdown →